• Is QALY Fair? Ethical Concerns for the Elderly and Disabled in Health Policy

    Is QALY Fair? Ethical Concerns for the Elderly and Disabled in Health Policy
    QALY

    In healthcare policy, striking a balance between equality and cost-effectiveness is an ongoing task. A common tool in this task is the Quality-Adjusted Life Year (QALY), a widely used measure in health economics for assessing the value of medical interventions. It merges both the length of life and quality of life (QoL) into a single number, enabling policymakers to compare treatments across varied health conditions. While the QALYs have been significant in informing healthcare resource utilization (HCRU) decisions, their application is becoming increasingly controversial due to the potential bias they cause against the elderly and individuals with disabilities.[1-3]

    Essentially, QALY considers a year of perfect health to be worth 1, and lesser health states are counted between 0 and 1 as per the perceived QoL. However, this approach can burden those who start at a lower baseline of health, for e.g. people with disabilities, the elderly, or those receiving palliative care; because their possible health gains may happen to be smaller or less “valuable” within this framework. The QALY is under scrutiny because such valuation unfairly treats some lives as worth less than others, a drawback reinforcing the concept of “states worse than death,” (SWTD), where negative QALY scores signify reduced overall utility with prolonged life.[3] In reality, this leads to underestimating life-extending therapies for already sidelined populations. These issues have triggered debates among researchers. For instance, in 2024, the introduction of the Protecting Health Care for All Patients Act (H.R.485) stirred a controversy by restricting the use of QALYs in federal healthcare decisions.[4] While both proponents and opponents continue to argue about the issue largely on theoretical basis, the ethical impact of assigning lower value to lives lived with disability or growing age continue to be an intense challenge to the metric’s equality.[1-3]

    A treatment that prolongs life is often ranked higher in QALYs for younger patients than for older ones, even though both benefit, because of the younger person’s longer life expectancy. Even if the treatment largely improves the older patient’s well-being, it may be deprioritized under strict QALY-based evaluations, efficiently assigning lower value to the lives of older individuals. This causes an ethical dilemma for researchers for whether they should account for age or remaining lifespan into decisions about whose care is “worth” more.[1, 2, 5]

    Moreover, the methods used to derive the QoL weights often fail to understand and depict the perspectives of individuals living with disabilities. These weights usually depend on a general public opinion about a life with certain weaknesses, rather than on self-assessments from people actually living with those impairments. This misrepresents those individuals, lowering valuations of disabled lives, emphasizing ableist assumptions about worth and happiness.[3]

    Therefore, the use of QALYs in healthcare decision-making poses a risk of causing age and disability biases, necessitating careful implementation. Health critics debate about how strongly supporting QALYs could result in unfair practices, where society inadvertently prefers the health demands of younger, able-bodied individuals. Although QALYs have been a helpful metric of health outcomes and maximum efficiency, they must be implemented with ethical consciousness, cultural sensitivity, and a motivation to select alternative or harmonizing guidelines that impartially represent the diverse human experience.

    Become A Certified HEOR Professional – Enrol yourself here!

    References

    1. Xie F, Zhou T, Humphries B, et al. Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses. Value Health. 2024; 27(6):706-712.
    2. Kocot E, Kotarba P, Dubas-Jakóbczyk K. The application of the QALY measure in the assessment of the effects of health interventions on an older population: a systematic scoping review. Arch Public Health. 2021 Nov 18;79(1):201.
    3. Schneider P. The QALY is ableist: on the unethical implications of health states worse than dead. Qual Life Res. 2022 May;31(5):1545-1552.
    4. US Congress. H.R.485 — 118th Congress (2023-2024): H.R.485 – Protecting Health Care for All Patients Act of 2023. Available online at: https://www.congress.gov/bill/118th-congress/house-bill/485
    5. Braithwaite RS. A Parsimonious Approach to Remediate Concerns about QALY-Based Discrimination. Medical Decision Making. 2024;45(2):214-219.
  • Healthcare Value Assessment: Beyond QALYs and Towards Holistic Outcome Measures

    Healthcare Value Assessment: Beyond QALYs and Towards Holistic Outcome Measures
    Healthcare Value Assessment: Beyond QALYs and Towards Holistic Outcome Measures

    Quality-Adjusted Life Years (QALY) is an important concept in health technology assessment since it provides a comprehensive assessment of the impact of diverse healthcare interventions by combining the length and quality of life into a single measure. QALY is measured by integrating life expectancy and quality of life (QoL). Various methods are employed to assess QoL, including structured questionnaires (such as generic questionnaires like EQ-5D, or disease-specific questionnaires), and preference-based interviews like time trade-off (TTO), standard gamble (SG), or visual analog scale (VAS).[1]

    The extensive use of QALYs is a result of several advantages. QALYs offer a standardized metric for comparing the effectiveness of various health interventions used in the management of diverse health conditions. This common scale helps policymakers and healthcare professionals prioritize interventions within a shared framework. The use of QALY can also promote objectivity in decision-making by treating individuals equally and avoiding biases related to age or health status. Additionally, it is possible to evaluate changes in health status over time by using QALYs, acknowledging the dynamic nature of health conditions.[1,2]

    QALY essentially involves evaluation and quantification of QoL through various means: since this results exclusively from a patient’s subjective assessment of the outcome of an intervention, QALYs also represent a patient-centric view of treatment outcomes, contrasting to the physician-centered efficacy and safety measures. This inclusion ensures a broader and more comprehensive perspective, aligning with the principle that public funding drives new treatments. QALY also contributes immensely to cost-utility analysis by allowing the calculation of cost-per-QALY, thereby helping policymakers navigate the complex landscape of resource allocation; this enables the maximization of health outcomes within budget constraints.[1,2]

    Despite these advantages, the QALY approach is not without its criticisms. The value dependency of QALY introduces subjectivity, with the choice of perspective (patient, service provider, or general public) impacting the analysis. Critics argue that disease-non-specific (generic) QoL tools like EQ-5D, while having the advantage of enabling comparison between diverse conditions, may oversimplify health states, especially in mental health cases, potentially neglecting important aspects valued by patients. Additionally, concerns about equity arise as QALY assumes equal social value for all, potentially leading to inequitable weighting based on characteristics such as sex and socioeconomic standing.[3,4]

    The age neutrality of QALY and its focus primarily on health service costs are additional drawbacks. These limitations raise questions about their universality and applicability across diverse healthcare scenarios. The discounting of future benefits also sparks ethical concerns regarding the fair distribution of healthcare resources over time. Decision-makers must grapple with these challenges, balancing the advantages and disadvantages of the QALY approach when employing it as a metric for healthcare decision-making.[3,4]

    In response to the acknowledged limitations of the QALY approach, several alternative metrics have been proposed, each presenting a distinct set of advantages and limitations. These alternatives aim to offer more comprehensive and nuanced evaluations of healthcare interventions, recognizing the diverse aspects of health outcomes. The willingness to Pay (WTP) approach serves as an alternative by incorporating individual preferences, and addresses a criticism of QALY for overlooking individual values. However, the WTP exercise is better suited for economic evaluations than for pure QoL analyses. Conducting a comprehensive WTP interview demands additional expertise in economic modeling, surveys, and analysis. WTP questionnaires also often involve more items and scale points, contributing to implementation complexities. These factors collectively make WTP a time and resource-intensive method.[5,6]

    Another metric seeking to address QALY’s limitations by focusing on a different aspect of well-being is Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWIST); however, this approach has challenges related to complexity and applicability, potentially restricting its application to a narrower range of healthcare interventions. Wellbeing-Adjusted Life Year (WELLBY) takes a broader approach by encompassing happiness and life satisfaction alongside health considerations, thereby addressing the limitation of QALY’s narrow focus on health outcomes; on the flip side, WELLBY faces challenges related to subjectivity and standardization, which could impact its reliability and consistency across evaluations.[5,6]

    Disability-Adjusted Life Year (DALY) offers a comprehensive evaluation by considering both premature mortality and years lived with disability, presenting a holistic perspective on disease burden. However, DALY’s criticisms include complexities in measuring disability, thereby potentially not capturing overall well-being satisfactorily, akin to looking at a ‘negative’ aspect to capture a ‘positive’ measure. Next, the Multi-Criteria Decision Analysis (MCDA) is a measure that evaluates options with conflicting criteria and selects the best solution accommodating complexity and stakeholder involvement. However, MCDA is often considered subjective and inconsistent and is also quite resource-intensive. Finally, the equal value of Life Years Gained (evLYG) strives for equitable assessments by considering age and baseline health, addressing QALY’s potential age bias; however, there are challenges in determining equal value across diverse health conditions.[5,6]

    The choice of a specific metric to measure QoL and QALY hinges on evaluation goals, contextual nuances, and stakeholder values. The ongoing evolution of healthcare value assessment methodologies reflects the dynamic nature of the field, with researchers and policymakers continually exploring and refining approaches to better capture the complexity of healthcare outcomes and their societal implications.[5,6]

    While numerous alternatives are available, QALY is undoubtedly the most frequently used metric despite its drawbacks and criticisms. The advantages of QALY, such as its comprehensive measurement, comparative analysis capabilities, and standardized metric, make it a practical tool for assessing the value of healthcare interventions. However, the subjectivity in quality assessment and limited applicability in certain scenarios might prompt consideration of alternative metrics discussed above. Ultimately, the quest for a complete tool for value assessment requires ongoing research, collaboration, and a commitment to refining existing methodologies to better align with the diverse and complex nature of healthcare interventions and outcomes.

    Become A Certified HEOR Professional – Enrol yourself here!

    References

    1. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. British medical bulletin. 2010 Dec 1;96(1):5-21.
    2. Prieto L, Sacristán JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003 Dec 19;1:80.
    3. Brazier J, Tsuchiya A. Improving cross-sector comparisons: going beyond the health-related QALY. Applied health economics and health policy. 2015 Dec;13:557-65.
    4. Pettitt DA, Raza S, Naughton B, Roscoe A, Ramakrishnan A, Ali A, Davies B, Dopson S, Hollander G, Smith J, Brindley D. The limitations of QALY: a literature review. Journal of Stem Cell Research and Therapy. 2016;6(4).
    5. Carlson JJ, Brouwer ED, Kim E, Wright P, McQueen RB. Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation. Value Health. 2020 Dec;23(12):1523-1533.
    6. Gafni A. Alternatives to the QALY measure for economic evaluations. Supportive care in cancer. 1997 Mar;5:105-11.